Trials Sponsors Conditions Drugs Pricing

Conditions

Blastic Plasmacytoid Dendritic Cell Neoplasm

Outcome Measures

Primary Outcomes (1)

Overall Survival Rate
From the date of diagnosis to the date of death, or from the date of diagnosis to the last follow-up date.
from the date of the IRB approval until June 30, 2019

Secondary Outcomes (3)

Therapeutic Response Rate
from the date of the IRB approval until June 30, 2019
Disease-free Survival Rate
from the date of the IRB approval until June 30, 2019
Number of Factors affecting overall survival
from the date of the IRB approval until June 30, 2019

Study Arms (1)

BPDCN diagnosis group

By review medical records Enroll patients diagnosed with BPDCN from January 1, 2000 to October 31, 2018

Eligibility Criteria

Sexall

Healthy VolunteersNo

Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

Sampling MethodProbability Sample

Study Population

This study is a retrospective study, in which patients with patients diagnosed with SCC tumors can participate, and patients who meet the selection criteria will be eligible. The purpose of this study is explorative and descriptive, and it is impossible to calculate the statistical background. Therefore, it is estimated that more than 40 patients are diagnosed with the disease in Korea so far.

You may qualify if:

Patients ≥ 18 years

Sponsors & Collaborators

Samsung Medical Center
Otherlead

Study Sites (1)

Samsung medical center

Seoul, Gang Nam, 676, South Korea

MeSH Terms

Conditions

Blastic Plasmacytoid Dendritic Cell Neoplasm

Condition Hierarchy (Ancestors)

Histiocytic Disorders, MalignantNeoplasms by Histologic TypeNeoplasmsLeukemiaLymphomaHematologic NeoplasmsNeoplasms by SiteSkin NeoplasmsHematologic DiseasesHemic and Lymphatic DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Study Officials

Seokjin Kim, M.D., PhD
Samsung Medical Center
PRINCIPAL INVESTIGATOR

Enrollment

36 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: OTHER
Time Perspective: RETROSPECTIVE
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Principal Investigator

Study Record Dates

First Submitted

May 22, 2019

First Posted

June 5, 2019

Study Start

April 30, 2019

Actual (reported)

Blastic Plasmacytoid Dendritic Cell Neoplasm in Korean Population.

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (3)

Study Arms (1)

BPDCN diagnosis group

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (3)

Study Arms (1)

BPDCN diagnosis group

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations